Polyamines in cancer

Advances in Clinical Chemistry

Volumn 54, Issue , 2011, Pages 45-70

  Paz, Edwin A ^a   Garcia Huidobro, Jenaro ^b   Ignatenko, Natalia A ^a  

^a UNIVERSITY OF ARIZONA   (United States)

^b UNIVERSITY OF ARIZONA   (United States)

Author keywords

APC; DFMO; EIF5A; K RAS; NSAIDs; ODC SNP; Polyamines; SLC3A2

Indexed keywords

ACYLTRANSFERASE; DIAMINE ACETYLTRANSFERASE; DIAMINE N-ACETYLTRANSFERASE; INITIATION FACTOR; INITIATION FACTOR 5A; ORNITHINE DECARBOXYLASE; POLYAMINE; RNA BINDING PROTEIN;

ANIMAL; BOOK; CHEMOPROPHYLAXIS; GENETICS; HUMAN; METABOLISM; NEOPLASM; PHYSIOLOGY; TUMOR SUPPRESSOR GENE;

ACETYLTRANSFERASES; ANIMALS; BIOGENIC POLYAMINES; CHEMOPREVENTION; GENES, APC; HUMANS; NEOPLASMS; ORNITHINE DECARBOXYLASE; PEPTIDE INITIATION FACTORS; RNA-BINDING PROTEINS;

EID: 79953904638     PISSN: 00652423     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-12-387025-4.00002-9     Document Type: Book

References (134)

1. Thomas T., Thomas T.J. Polyamines in cell growth and cell death: molecular mechanisms and therapeutic applications. Cell. Mol. Life Sci. 2001, 5:244-258.
2. Tabor H., Hafner E.W., Tabor C.W. Construction of an Escherichia coli strain unable to synthesize putrescine, spermidine, or cadaverine: characterization of two genes controlling lysine decarboxylase. J. Bacteriol. 1980, 144:952-956.
3. Balasundaram D., Tabor C.W., Tabor H. Spermidine or spermine is essential for the aerobic growth of Saccharomyces cerevisiae. Proc. Natl. Acad. Sci. USA 1991, 88:5872-5876.
4. Lux G.D., Marton L.J., Baylin S.B. Ornithine decarboxylase is important in intestinal mucosal maturation and recovery from injury in rats. Science 1980, 210:195-198.
5. McCormack S.A., Johnson L.R. Polyamines and cell migration. J. Physiol. Pharmacol. 2001, 52:327-349.
6. Igarashi K., Kashiwagi K. Polyamines: mysterious modulators of cellular functions. Biochem. Biophys. Res. Commun. 2000, 271:559-564.
7. Matsufuji S., Matsufuji T., Miyazaki Y., Murakami Y., Atkins J.F., Gesteland R.F., et al. Autoregulatory frameshifting in decoding mammalian ornithine decarboxylase antizyme. Cell 1995, 80:51-60.
8. Basuroy U.K., Gerner E.W. Emerging concepts in targeting the polyamine metabolic pathway in epithelial cancer chemoprevention and chemotherapy. J. Biochem. 2006, 139:27-33.
9. Casero R.A., Marton L.J. Targeting polyamine metabolism and function in cancer and other hyperproliferative diseases. Nat. Rev. Drug Discov. 2007, 6:373-390.
10. Childs A.C., Mehta D.J., Gerner E.W. Polyamine-dependent gene expression. Cell. Mol. Life Sci. 2003, 60:1394-1406.
11. Gerner E.W., Meyskens F.L. Polyamines and cancer: old molecules, new understanding. Nat. Rev. Cancer 2004, 4:781-792.
12. Janne J., Alhonen L., Pietila M., Keinanen T.A. Genetic approaches to the cellular functions of polyamines in mammals. Eur. J. Biochem. 2004, 271:77-894.
13. Pegg A.E. Polyamine metabolism and its importance in neoplastic growth and a target for chemotherapy. Cancer Res. 1988, 48:759-774.
14. Pegg A.E. Mammalian polyamine metabolism and function. IUBMB Life 2009, 61:880-894.
15. Pendeville H., Carpino N., Marine J.C., Takahashi Y., Muller M., Martial J.A., et al. The ornithine decarboxylase gene is essential for cell survival during early murine development. Mol. Cell. Biol. 2001, 21:6549-6558.
16. Coffino P. Regulation of cellular polyamines by antizyme. Nat. Rev. Mol. Cell Biol. 2001, 2:188-194.
17. Kahana C. Regulation of cellular polyamine levels and cellular proliferation by antizyme and antizyme inhibitor. Essays Biochem. 2009, 46:47-61.
18. Hoshino K., Momiyama E., Yoshida K., Nishimura K., Sakai S., Toida T., et al. Polyamine transport by mammalian cells and mitochondria: role of antizyme and glycosaminoglycans. J. Biol. Chem. 2005, 280:42801-42808.
19. Mitchell J.L., Judd G.G., Bareyal-Leyser A., Ling S.Y. Feedback repression of polyamine transport is mediated by antizyme in mammalian tissue-culture cells. Biochem. J. 1994, 299(Pt 1):19-22.
20. Hayashi S., Murakami Y., Matsufuji S. Ornithine decarboxylase antizyme: a novel type of regulatory protein. Trends Biochem. Sci. 1996, 21:27-30.
21. Pegg A.E. Regulation of ornithine decarboxylase. J. Biol. Chem. 2006, 281:14529-14532.
22. Nilsson J.A., Maclean K.H., Keller U.B., Pendeville H., Baudino T.A., Cleveland J.L. Mnt loss triggers Myc transcription targets, proliferation, apoptosis, and transformation. Mol. Cell. Biol. 2004, 24:1560-1569.
23. Pegg A.E., Xiong H., Feith D.J., Shantz L.M. S-adenosylmethionine decarboxylase: structure, function and regulation by polyamines. Biochem. Soc. Trans. 1998, 26:580-586.
24. Kahana C. Ubiquitin dependent and independent protein degradation in the regulation of cellular polyamines. Amino Acids 2007, 33:225-230.
25. Yerlikaya A., Stanley B.A. S-adenosylmethionine decarboxylase degradation by the 26 S proteasome is accelerated by substrate-mediated transamination. J. Biol. Chem. 2004, 279:12469-12478.
26. Forshell T.P., Rimpi S., Nilsson J.A. Chemoprevention of B-cell lymphomas by inhibition of the Myc target spermidine synthase. Cancer Prev. Res. (Phila.) 2010, 3:140-147.
27. Pegg A.E. Spermidine/spermine-N(1)-acetyltransferase: a key metabolic regulator. Am. J. Physiol. Endocrinol. Metab. 2008, 294:E995-1010.
28. Golab F., Kadkhodaee M., Zahmatkesh M., Hedayati M., Arab H., Schuster R., et al. Ischemic and non-ischemic acute kidney injury cause hepatic damage. Kidney Int. 2009, 75:783-792.
29. Wang Y., Casero R.A. Mammalian polyamine catabolism: a therapeutic target, a pathological problem, or both?. J. Biochem. 2006, 139:17-25.
30. Zahedi K., Lentsch A.B., Okaya T., Barone S., Sakai N., Witte D.P., et al. Spermidine/spermine-N1-acetyltransferase ablation protects against liver and kidney ischemia-reperfusion injury in mice. Am. J. Physiol. 2009, 296:G899-G909.
31. Wang Y., Devereux W., Stewart T.M., Casero R.A. Cloning and characterization of human polyamine-modulated factor-1, a transcriptional cofactor that regulates the transcription of the spermidine/spermine N(1)-acetyltransferase gene. J. Biol. Chem. 1999, 274:22095-22101.
32. Casero R.A., Pegg A.E. Polyamine catabolism and disease. Biochem. J. 2009, 421:323-338.
33. Ivanov I.P., Atkins J.F., Michael A.J. A profusion of upstream open reading frame mechanisms in polyamine-responsive translational regulation. Nucleic Acids Res. 2010, 38:353-359.
34. Larque E., Sabater-Molina M., Zamora S. Biological significance of dietary polyamines. Nutrition 2007, 23:87-95.
35. Belting M., Mani K., Jonsson M., Cheng F., Sandgren S., Jonsson S., et al. Glypican-1 is a vehicle for polyamine uptake in mammalian cells: a pivotal role for nitrosothiol-derived nitric oxide. J. Biol. Chem. 2003, 278:47181-47189.
36. Roy U.K., Rial N.S., Kachel K.L., Gerner E.W. Activated K-RAS increases polyamine uptake in human colon cancer cells through modulation of caveolar endocytosis. Mol. Carcinog. 2008, 47:538-553.
37. Uemura T., Stringer D.E., Blohm-Mangone K.A., Gerner E.W. Polyamine transport is mediated by both endocytic and solute carrier transport mechanisms in the gastrointestinal tract. Am. J. Physiol. 2010, 299:G517-G522.
38. Xie X., Gillies R.J., Gerner E.W. Characterization of a diamine exporter in Chinese hamster ovary cells and identification of specific polyamine substrates. J. Biol. Chem. 1997, 272:20484-20489.
39. Uemura T., Yerushalmi H.F., Tsaprailis G., Stringer D.E., Pastorian K.E., Hawel L. Identification and characterization of a diamine exporter in colon epithelial cells. J. Biol. Chem. 2008, 283:26428-26435.
40. Jemal A., Siegel R., Xu J., Ward E. Cancer statistics. CA Cancer J. Clin. 2010, 60:277-300.
41. Fearon E.R., Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990, 61:759-767.
42. Russell D., Snyder S.H. Amine synthesis in rapidly growing tissues: ornithine decarboxylase activity in regenerating rat liver, chick embryo, and various tumors. Proc. Natl. Acad. Sci. USA 1968, 60:1420-1427.
43. Ahmad N., Gilliam A.C., Katiyar S.K., O'Brien T.G., Mukhtar H. A definitive role of ornithine decarboxylase in photocarcinogenesis. Am. J. Pathol. 2001, 159:885-892.
44. Marsh J.P., Mossman B.T. Role of asbestos and active oxygen species in activation and expression of ornithine decarboxylase in hamster tracheal epithelial cells. Cancer Res. 1991, 51:167-173.
45. Mohan R.R., Challa A., Gupta S., Bostwick D.G., Ahmad N., Agarwal R., et al. Overexpression of ornithine decarboxylase in prostate cancer and prostatic fluid in humans. Clin. Cancer Res. 1999, 5:143-147.
46. Shantz L.M., Levin V.A. Regulation of ornithine decarboxylase during oncogenic transformation: mechanisms and therapeutic potential. Amino Acids 2007, 33:213-223.
47. George K., Iacobucci A., Uitto J., O'Brien T.G. Identification of an X-linked locus modifying mouse skin tumor susceptibility. Mol. Carcinog. 2005, 44:212-218.
48. Hayes C.S., DeFeo K., Lan L., Paul B., Sell C., Gilmour S.K. Elevated levels of ornithine decarboxylase cooperate with Raf/ERK activation to convert normal keratinocytes into invasive malignant cells. Oncogene 2006, 25:1543-1553.
49. Feith D.J., Origanti S., Shoop P.L., Sass-Kuhn S., Shantz L.M. Tumor suppressor activity of ODC antizyme in MEK-driven skin tumorigenesis. Carcinogenesis 2006, 27:1090-1098.
50. Feith D.J., Shantz L.M., Pegg A.E. Targeted antizyme expression in the skin of transgenic mice reduces tumor promoter induction of ornithine decarboxylase and decreases sensitivity to chemical carcinogenesis. Cancer Res. 2001, 61:6073-6081.
51. Tang X., Kim A.L., Feith D.J., Pegg A.E., Russo J., Zhang H., et al. Ornithine decarboxylase is a target for chemoprevention of basal and squamous cell carcinomas in Ptch1+/- mice. J. Clin. Invest. 2004, 113:867-875.
52. Giardiello F.M., Hamilton S.R., Hylind L.M., Yang V.W., Tamez P., Casero R.A. Ornithine decarboxylase and polyamines in familial adenomatous polyposis. Cancer Res. 1997, 57:199-201.
53. Luk G.D., Baylin S.B. Ornithine decarboxylase as a biologic marker in familial colonic polyposis. N. Engl. J. Med. 1984, 311:80-83.
54. Fultz K.E., Gerner E.W. APC-dependent regulation of ornithine decarboxylase in human colon tumor cells. Mol. Carcinog. 2002, 34:10-18.
55. Mishra L., Shetty K., Tang Y., Stuart A., Byers S.W. The role of TGF-β and Wnt signaling in gastrointestinal stem cells and cancer. Oncogene 2005, 24:5775-5789.
56. Groden J., Thliveris A., Samowitz W., Carlson M., Gelbert L., Albertson H., et al. Identification and characterization of the familial adenomatous polyposis coli gene. Cell 1991, 66:589-600.
57. Kinzler K.W., Nilbert M.C., Su L.K., Vogelstein B., Bryan T.M., Levy D.B., et al. Identification of FAP locus genes from chromosome 5q21. Science 1991, 253:661.
58. Erdman S.H., Ignatenko N.A., Powell M.B., Blohm-Mangone K.A., Holubec H., Guillen-Rodrigez J.M., et al. APC-dependent changes in expression of genes influencing polyamine metabolism, and consequences for gastrointestinal carcinogenesis, in the Min mouse. Carcinogenesis 1999, 20:1709-1713.
59. He T.C., Sparks A.B., Rago C., Hermeking H., Zawel L., da Costa L.T., et al. Identification of c-MYC as a target of the APC pathway. Science 1998, 281:1509-1512.
60. Reya T., Clevers H. Wnt signalling in stem cells and cancer. Nature 2005, 434:843-850.
61. Hermeking H. The MYC oncogene as a cancer drug target. Curr. Cancer Drug Targets 2003, 3:163-175.
62. Ignatenko N.A., Holubec H., Besselsen D.G., Blohm-Mangone K.A., Padilla-Torres J.L., Nagle R.B., et al. Role of c-Myc in intestinal tumorigenesis of the ApcMin/+ mouse. Cancer Biol. Ther. 2006, 5:1658-1664.
63. Jain M., Arvanitis C., Chu K., Dewey W., Leonhardi E., Trinh M., et al. Sustained loss of a neoplastic phenotype by brief inactivation of MYC. Science 2002, 297:102-104.
64. Seenisamy J., Bashyam S., Gokhale V., Vankayalapati H., Sun D., Siddiquui-Jain A., et al. Design and synthesis of an expanded porphyrin that has selectivity for the c-MYC G-quadruplex structure. J. Am. Chem. Soc. 2005, 127:2944-2959.
65. Seenisamy J., Rezler E.M., Powell T.J., Tye D., Gokhale V., Joshi C.S., et al. The dynamic character of the G-quadruplex element in the c-MYC promoter and modification by TMPyP4. J. Am. Chem. Soc. 2004, 126:8702-8709.
66. Bos J.L. ras oncogenes in human cancer: a review. Cancer Res. 1989, 49:4682-4689.
67. Pruitt K., Der C.J. Ras and Rho regulation of the cell cycle and oncogenesis. Cancer Lett. 2001, 171:1-10.
68. Mitsushita J., Lambeth J.D., Kamata T. The superoxide-generating oxidase Nox1 is functionally required for Ras oncogene transformation. Cancer Res. 2004, 64:3580-3585.
69. Holtta E., Sistonen L., Alitalo K. The mechanisms of ornithine decarboxylase deregulation in c-Ha-ras oncogene-transformed NIH 3T3 cells. J. Biol. Chem. 1988, 263:4500-4507.
70. Ignatenko N.A., Zhang H., Watts G.S., Skovan B.A., Stringer D.E., Gerner E.W. The chemopreventive agent alpha-difluoromethylornithine blocks Ki-ras-dependent tumor formation and specific gene expression in Caco-2 cells. Mol. Carcinog. 2004, 39:221-233.
71. Shantz L.M. Transcriptional and translational control of ornithine decarboxylase during Ras transformation. Biochem. J. 2004, 377:257-264.
72. Janne J., Alhonen L., Pietila M., Keinanen T.A., Uimari A., Hyvonen M.T., et al. Genetic manipulation of polyamine catabolism in rodents. J. Biochem. 2006, 139:155-160.
73. Pirinen E., Kuulasmaa T., Pietila M., Heikkinen S., Tusa M., Itkonen P., et al. Enhanced polyamine catabolism alters homeostatic control of white adipose tissue mass, energy expenditure, and glucose metabolism. Mol. Cell. Biol. 2007, 27:4953-4967.
74. Taylor M.T., Lawson K.R., Ignatenko N.A., Marek S.E., Stringer D.E., Skovan B.A., et al. Sulindac sulfone inhibits K-ras-dependent cyclooxygenase-2 expression in human colon cancer cells. Cancer Res. 2000, 60:6607-6610.
75. Ignatenko N.A., Babbar N., Mehta D., Casero R.A., Gerner E.W. Suppression of polyamine catabolism by activated Ki-ras in human colon cancer cells. Mol. Carcinog. 2004, 39:91-102.
76. Tucker J.M., Murphy J.T., Kisiel N., Diegelman P., Barbour K.W., Davis C., et al. Potent modulation of intestinal tumorigenesis in Apcmin/+ mice by the polyamine catabolic enzyme spermidine/spermine N1-acetyltransferase. Cancer Res. 2005, 65:5390-5398.
77. Nilsson J.A., Keller U.B., Baudino T.A., Yang C., Norton S., Old J.A., et al. Targeting ornithine decarboxylase in Myc-induced lymphomagenesis prevents tumor formation. Cancer Cell 2005, 7:433-444.
78. Hessels J., Kingma A.W., Ferwerda H., Keij J., van den Berg G.A., Muskiet F.A. Microbial flora in the gastrointestinal tract abolishes cytostatic effects of alpha-difluoromethylornithine in vivo. Int. J. Cancer 1989, 43:1155-1164.
79. Quemener V., Moulinoux J.P., Havouis R., Seiler N. Polyamine deprivation enhances antitumoral efficacy of chemotherapy. Anticancer Res. 1992, 12:1447-1453.
80. Bachrach U., Seiler N. Formation of acetylpolyamines and putrescine from spermidine by normal and transformed chick embryo fibroblasts. Cancer Res. 1981, 41:1205-1208.
81. Brown D.A., London E. Functions of lipid rafts in biological membranes. Annu. Rev. Cell Dev. Biol. 1998, 14:111-136.
82. Goetz J.G., Lajoie P., Wiseman S.M., Nabi I.R. Caveolin-1 in tumor progression: the good, the bad and the ugly. Cancer Metastasis Rev. 2008, 27:715-735.
83. Guo Y., Harris R.B., Rosson D., Boorman D., O'Brien T.G. Functional analysis of human ornithine decarboxylase alleles. Cancer Res. 2000, 60:6314-6317.
84. Walhout A.J., van der Vliet P.C., Timmers H.T. Sequences flanking the E-box contribute to cooperative binding by c-Myc/Max heterodimers to adjacent binding sites. Biochim. Biophys. Acta 1998, 1397:189-201.
85. Fenoglio C.M., Lane N. The anatomical precursor of colorectal carcinoma. Cancer 1974, 34:819-823.
86. Morson B.C. Evolution of cancer of the colon and rectum. Cancer 1974, 34:845-849.
87. Baron J.A., Beach M., Mandel J.S., Van Stolk R.U., Haile R.W., Sandler R.S., et al. Calcium supplements for the prevention of colorectal adenomas. N. Engl. J. Med. 1999, 340:101.
88. Winawer S.J., Zauber A.G., Ho M.N., O'Brien M.J., Gottlieb L.S., Sternberg S.S., et al. Prevention of colorectal cancer by colonoscopic polypectomy. N. Engl. J. Med. 1993, 32:1977-1981.
89. Kronborg O., Fenger C. Clinical evidence for the adenoma-carcinoma sequence. Eur. J. Cancer Prev. 1999, 8:S73-S86.
90. Martínez M.E., Sampliner R., Marshall J.R., Bhattacharyya A.K., Reid M.E., Alberts D.S. Adenoma characteristics as risk factors for recurrence of advanced adenomas. Gastroenterology 2001, 120:1077-1083.
91. Martinez M.E., O'Brien T.G., Fultz K.E., Babbar N., Yerushalmi H., Qu N., et al. Pronounced reduction in adenoma recurrence associated with aspirin use and a polymorphism in the ornithine decarboxylase gene. Proc. Natl. Acad. Sci. USA 2003, 100:7859-7864.
92. Baron J.A. Epidemiology of non-steroidal anti-inflammatory drugs and cancer. Prog. Exp. Tumor Res. 2003, 37:1-24.
93. Barry E.L., Baron J.A., Bhat S., Grau M.V., Burke C.A., Sandler R.S., et al. Ornithine decarboxylase polymorphism modification of response to aspirin treatment for colorectal adenoma prevention. J. Natl. Cancer Inst. 2006, 98:1494-1500.
94. Hubner R.A., Muir K.R., Liu J.F., Logan R.F.A., Grainge M.J., Houlston R.S. Ornithine decarboxylase G316A genotype is prognostic for colorectal adenoma recurrence and predicts efficacy of aspirin chemoprevention. Clin. Cancer Res. 2008, 14:2303-2309.
95. Zell J.A., Pelot D., Chen W.P., McLaren C.E., Gerner E.W., Meyskens F.L. Risk of cardiovascular events in a randomized placebo-controlled, double-blind trial of difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas. Cancer Prev. Res. (Phila.) 2009, 2:209-212.
96. Hughes D.J., Hlavatá I., Soucek P., Pardini B., Naccarati A., Vodickova L., et al. Ornithine decarboxylase G316A genotype and colorectal cancer risk. Colorectal Dis. 2010, accession number 20456464.
97. Zanelli C.F., Valentini S.R. Is there a role for eIF5A in translation?. Amino Acids 2007, 33:351-358.
98. Benne R., Brown-Luedi M.L., Hershey J.W. Purification and characterization of protein synthesis initiation factors eIF-1, eIF-4C, eIF-4D, and eIF-5 from rabbit reticulocytes. J. Biol. Chem. 1978, 253:3070-3077.
99. Kang H.A., Hershey J.W. Effect of initiation factor eIF-5A depletion on protein synthesis and proliferation of Saccharomyces cerevisiae. J. Biol. Chem. 1994, 269:3934-3940.
100. Schnier J., Schwelberger H.G., Smit-McBride Z., Kang H.A., Hershey J.W. Translation initiation factor 5A and its hypusine modification are essential for cell viability in the yeast Saccharomyces cerevisiae. Mol. Cell. Biol. 1991, 11:3105-3114.
101. Chattopadhyay M.K., Park M.H., Tabor H. Hypusine modification for growth is the major function of spermidine in Saccharomyces cerevisiae polyamine auxotrophs grown in limiting spermidine. Proc. Natl. Acad. Sci. USA 2008, 105:6554-6559.
102. Park M.H. The post-translational synthesis of a polyamine-derived amino acid, hypusine, in the eukaryotic translation initiation factor 5A (eIF5A). J. Biochem. 2006, 139:161-169.
103. Lebska M., Ciesielski A., Szymona L., Godecka L., Lewandowska-Gnatowska E., Szczegielniak J., et al. Phosphorylation of maize eukaryotic translation initiation factor 5A (eIF5A) by casein kinase 2: identification of phosphorylated residue and influence on intracellular localization of eIF5A. J. Biol. Chem. 2006, 285:6217-6226.
104. Lee S.B., Park J.H., Kaevel J., Sramkova M., Weigert R., Park M.H. The effect of hypusine modification on the intracellular localization of eIF5A. Biochem. Biophys. Res. Commun. 2009, 383:497-502.
105. Kyrpides N.C., Woese C.R. Universally conserved translation initiation factors. Proc. Natl. Acad. Sci. USA 1998, 95:224-228.
106. Blaha G., Stanley R.E., Steitz T.A. Formation of the first peptide bond: the structure of EF-P bound to the 70S ribosome. Science 2009, 325:966-970.
107. Zanelli C.F., Maragno A.L., Gregio A.P., Kornili S., Pandolfi J.P., Mestriner C.A., et al. eIF5A binds to translational machinery components and affects translation in yeast. Biochem. Biophys. Res. Commun. 2006, 348:1358-1366.
108. Saini P., Eyler D.E., Green R., Dever T.E. Hypusine-containing protein eIF5A promotes translation elongation. Nature 2009, 459:118-121.
109. Li C.H., Ohn T., Ivanov P., Tisdale S., Anderson P. eIF5A promotes translation elongation, polysome disassembly and stress granule assembly. PLoS One 2010, 5:e9942.
110. Jenkins Z.A., Haag P.G., Johansson H.E. Human eIF5A2 on chromosome 3q25-q27 is a phylogenetically conserved vertebrate variant of eukaryotic translation initiation factor 5A with tissue-specific expression. Genomics 2001, 71:101-109.
111. Clement P.M., Henderson C.A., Jenkins Z.A., Smit-McBride Z., Wolff E.C., Hershey J.W., et al. Identification and characterization of eukaryotic initiation factor 5A-2. Eur. J. Biochem. 2003, 270:4254-4263.
112. Guan X.Y., Fung J.M., Ma N.F., Lau S.H., Tai L.S., Xie D., et al. Oncogenic role of eIF-5A2 in the development of ovarian cancer. Cancer Res. 2004, 64:4197-4200.
113. Zender L., Xue W., Zuber J., Seminghini C.P., Krasnitz A., Ma B., et al. An oncogenomics-based in vivo RNAi screen identifies tumor suppressors in liver cancer. Cell 2008, 135:852-864.
114. Lipowsky G., Bischoff F.R., Schwarzmaier P., Kraft R., Kostka S., Hartmann E., et al. Exportin 4: a mediator of a novel nuclear export pathway in higher eukaryotes. EMBO J. 2000, 19:4362-4371.
115. Kurisaki A., Kurisaki K., Kowanetz M., Sugino H., Yoneda Y., Heldin C.H., et al. The mechanism of nuclear export of Smad3 involves exportin 4 and Ran. Mol. Cell. Biol. 2006, 26:1318-1332.
116. Meyskens F.L., McLaren C.E., Pelot D., Fujikawa-Brooks S., Carpenter P.M., Hawk E., et al. Difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas: a randomized placebo-controlled, double-blind trial. Cancer Prev. Res. 2008, 1:32-38.
117. Shapiro J., Lui H. Vaniqa-eflornithine 13.9% cream. Skin Ther. Lett. 2001, 6:1-3.
118. Metcalf B.W., Bey P., Danzin C., Jung M.J., Cagara P., Ververt J.P. Catalytic irreversible inhibition of mammalian ornithine decarboxylase (E.C. 4.1.1.17) by substrate and product analogues. J. Am. Chem. Soc. 1978, 100:2551-2553.
119. Poulin R., Lu L., Ackermann B., Bey P., Pegg A.E. Mechanism of the irreversible inactivation of mouse ornithine decarboxylase by alpha-difluoromethylornithine. Characterization of sequences at the inhibitor and coenzyme binding sites. J. Biol. Chem. 1992, 267:150-158.
120. Coleman C.S., Stanley B.A., Pegg A.E. Effect of mutations at active site residues on the activity of ornithine decarboxylase and its inhibition by active site-directed irreversible inhibitors. J. Biol. Chem. 1993, 268:24572-24579.
121. Yerushalmi H.F., Besselsen D.G., Ignatenko N.A., Blohm-Mangone K.A., Padilla-Torres J.L., Stringer D.E., et al. Role of polyamines in arginine-dependent colon carcinogenesis in Apc(Min) (/+) mice. Mol. Carcinog. 2006, 45:764-773.
122. Meyskens F.L. Development of difluoromethyl-ornithine and Bowman-Birk inhibitor as chemopreventive agents by assessment of relevant biomarker modulation: some lessons learned. IARC Sci. Publ. 2001, 154:49-55.
123. Lawson K.R., Ignatenko N.A., Piazza G.A., Cui H., Gerner E.W. Influence of K-ras activation on the survival responses of Caco-2 cells to the chemopreventive agents sulindac and difluoromethylornithine. Cancer Epidemiol. Biomark. Prev. 2000, 9:1155-1162.
124. Lan L., Trempus C., Gilmour S.K. Inhibition of ornithine decarboxylase (ODC) decreases tumor vascularization and reverses spontaneous tumors in ODC/Ras transgenic mice. Cancer Res. 2000, 60:5696-5703.
125. Babbar N., Ignatenko N.A., Casero R.A., Gerner E.W. Cyclooxygenase-independent induction of apoptosis by sulindac sulfone is mediated by polyamines in colon cancer. J. Biol. Chem. 2003, 278:47762-47775.
126. Babbar N., Gerner E.W., Casero R.A. Induction of spermidine/spermine N1-acetyltransferase (SSAT) by aspirin in Caco-2 colon cancer cells. Biochem. J. 2006, 394:317-324.
127. Ignatenko N.A., Besselsen D.G., Roy U.K., Stringer D.E., Blohm-Mangone K.A., Padilla-Torres J.L., et al. Dietary putrescine reduces the intestinal anticarcinogenic activity of sulindac in a murine model of familial adenomatous polyposis. Nutr. Cancer 2006, 56:172-181.
128. Huang Y., Pledgie A., Casero R.A., Davidson N.E. Molecular mechanisms of polyamine analogs in cancer cells. Anticancer Drugs 2005, 16:229-241.
129. Ignatenko N.A., Yerushalmi H.F., Pandey R., Kachel K.L., Stringer D.E., Marton L.J., et al. Gene expression analysis of HCT116 colon tumor-derived cells treated with the polyamine analog PG-11047. Cancer Genomics Proteomics 2009, 6:161-175.
130. Zell J.A., Ignatenko N.A., Yerushalmi H.F., Ziogas A., Besselsen D.G., Gerner E.W., et al. Risk and risk reduction involving arginine intake and meat consumption in colorectal tumorigenesis and survival. Int. J. Cancer 2007, 120:459-468.
131. Ignatenko N.A., Besselsen D.G., Stringer D.E., Blohm-Mangone K.A., Cui H., Gerner E.W. Combination chemoprevention of intestinal carcinogenesis in a murine model of familial adenomatous polyposis. Nutr. Cancer 2008, 60(Suppl. 1):30-35.
132. Meyskens F.L., Emerson S.S., Pelot D., Meshkinpour H., Shassetz L.R., Einspahr J., et al. Dose de-escalation chemoprevention trial of alpha-difluoromethylornithine in patients with colon polyps. J. Natl. Cancer Inst. 1994, 86:1122-1130.
133. Meyskens F.L., Gerner E.W., Emerson S., Pelot D., Durbin T., Doyle K., et al. Effect of alpha-difluoromethylornithine on rectal mucosal levels of polyamines in a randomized, double-blinded trial for colon cancer prevention. J. Natl. Cancer Inst. 1998, 90:1212-1218.
134. Burns M.R., Graminski G.F., Weeks R.S., Chen Y., O'Brien T.G. Lipophilic lysine-spermine conjugates are potent polyamine transport inhibitors for use in combination with a polyamine biosynthesis inhibitor. J. Med. Chem. 2009, 52:1983-1993.